DAVY VIEW

2019 was a year of stabilisation for Mainstay after the disappointing ReActiv8-B trial results (December 2018). 2020 should be better with progress being made in key strategic areas. Dialogue with the FDA is progressing well on the group’s PMA application for ReActiv8, with an approval decision expected in end-2020 that could unlock the US market. The commercial strategy refined in Germany should support 2020 growth, and the platform could be replicated to propel growth in new markets: UK launch expected H1-20; Australia launch expected Q4-20/Q1-21.